In this work, we hypothesized that sHDL encapsulating docetaxel chemotherapy would enhance the delivery of docetaxel to colon adenocarcinoma cells and that combining this single-agent therapy with TLR9 agonist CpG would augment the antitumor efficacy of the monotherapy, suppress tumor growth, and prolong animal survival. Here, TLR9 is linked to neoplasm.